Mortality from pneumonia (ICD-10 J12-J18 equivalent to ICD-9 480-486). To reduce deaths from pneumonia. Legacy unique identifier: P00597

In 2022, the highest death rate from influenza and pneumonia in Canada per 100,000 population was reported among those aged 90 years and older, with around *** deaths. Individuals between 85 and 89 years followed, with a mortality rate from influenza and pneumonia of almost *** deaths per 100,000 people. This statistic displays the death rate from influenza and pneumonia per 100,000 population in Canada during 2022, by age.

In 2020, approximately ** men and ** women per 100,000 population died as a result of pneumonia in England and Wales. In every year in the provided time interval the mortality rate was higher among men, although both genders have experienced a general decline in deaths from pneumonia. Regionally, the North West had the highest mortality rate for both genders.

Pneumonia risk groups

The age groups most at risk from pneumonia is undoubtedly the older age groups. In 2021, in England and Wales, pneumonia was the cause of death for approximately *** thousand over ** year olds, of which *** thousand were women. Furthermore, around *** thousand individuals aged between 80 and 89 years lost their lives due to pneumonia in 2021.

Prevalence of other lung diseases

In England and Wales in 2019, the mortality rate from bronchitis for men was around ** per 100,000 population, while the rate for women was approximately **. The mortality rate for bronchitis was higher than pneumonia, this is caused in part by the large decline in the mortality rate of pneumonia since the year 2000.

Deaths from pneumonia. Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

This statistic shows the deaths with pneumonia as an underlying cause in England and Wales in 2023, by age and gender. In this year, pneumonia was the underlying cause of over 4.6 thousand deaths for women aged 90 years and older.

This statistic shows the number of deaths from pneumonia in Taiwan in 2023, by age group. That year, ** infants younger than *** year died from pneumonia in Taiwan, whereas ***** children between *** and 14 years old were victims of pneumonia. The largest share of patients who died from the disease were senior citizens aged 65 and above.

Statistical information on confirmed cases and deaths of severe special infectious pneumonia starting in 2020, with secondary statistical tables stratified by region, age group, and gender. This data set is updated once a day according to the system's fixed schedule. At present, there are more cases of severe special infectious pneumonia imported from overseas than those confirmed by tests at airports or centralized quarantine stations and immediately isolated and treated, so their county and city information is not marked.

Deaths counts for influenza, pneumonia, and COVID-19 reported to NCHS by week ending date, by state and HHS region, and age group.

TABLE III. Deaths in 122 U.S. cities – 2016. 122 Cities Mortality Reporting System — Each week, the vital statistics offices of 122 cities across the United States report the total number of death certificates processed and the number of those for which pneumonia or influenza was listed as the underlying or contributing cause of death by age group (Under 28 days, 28 days –1 year, 1-14 years, 15-24 years, 25-44 years, 45-64 years, 65-74 years, 75-84 years, and ≥ 85 years).

FOOTNOTE: U: Unavailable. —: No reported cases. * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

† Pneumonia and influenza.

§ Total includes unknown ages.

Age-stratified incidence (per 100,000 persons per year) and case-fatality rate of invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and community-acquired pneumonia (CAP).

Number of deaths and age-specific mortality rates for selected grouped causes, by age group and sex, 2000 to most recent year.

Influenza and pneumonia caused around 12.3 deaths in the U.S. per 100,000 population in 2019. Influenza and pneumonia are among the leading causes of death in the United States, accounting for around 1.6 percent of all deaths in 2020. Influenza, or the flu, is a viral infection that is highly contagious and especially common in the winter season. Influenza is a common cause of pneumonia, although most cases of the flu do not develop into pneumonia. Pneumonia is an infection or inflammation of the lungs and is particularly deadly among young children and the elderly.

Influenza cases

Influenza is very common in the United States, with an estimated 35 million cases reported in 2019-2020. Common symptoms of the flu include cough, fever, runny or stuffy nose, sore throat and headache. Symptoms can be mild but can also be severe enough to require medical attention. In 2019-2020, there were around 16 million influenza-related medical visits in the United States.

Prevention

To prevent contracting the flu people can take everyday precautions such as regularly washing their hands and avoiding those who are sick, but the best way to prevent the flu is by receiving the flu vaccination every year. Receiving a flu vaccination is especially important for young children and the elderly as they are most susceptible to flu complications and associated death. In 2021, around 75 percent of those aged 65 years and older received a flu vaccine, while only 38 percent of those aged 18 to 49 years had done so.

BackgroundThere is only limited information on mortality over extended periods in hospitalized patients with pneumococcal community-acquired pneumonia (CAP). We aimed to evaluate the 30-day mortality and whether is changed over a 20-year period among immunocompetent adults hospitalized with pneumococcal CAP.MethodsWe conducted a retrospective observational study of data that were prospectively collected at the Hospital Clinic of Barcelona of all adult patients hospitalized with diagnosis of pneumococcal CAP over a 20-year period. To aid analysis, results were divided into four periods of 5 years each (1997–2001, 2002–2006, 2007–2011, 2012–2016). The primary outcome was 30-day mortality, but secondary outcomes included intensive care unit (ICU) admission, lengths of hospital and ICU-stays, ICU-mortality, and need of mechanical ventilation.ResultsFrom a cohort of 6,403 patients with CAP, we analyzed the data for 1,120 (17%) adults with a diagnosis of pneumococcal CAP. Over time, we observed decreases in the rates of alcohol consumption, smoking, influenza vaccination, and older patients (age ≥65 years), but increases in admissions to ICU and the need for non-invasive mechanical ventilation. The overall 30-day mortality rate was 8% (95% confidence interval, 6%–9%; 84 of 1,120 patients) and did not change significantly between periods (p = 0.33). Although, we observed a decrease in ICU-mortality comparing the first period (26%) to the second one (10%), statistical differences disappeared with adjustment (p0.38).ConclusionOver time, 30-day mortality of hospitalized pneumococcal CAP did not change significantly. Nor did it change in the propensity-adjusted multivariable analysis. Since mortality in pneumococcal pneumonia has remained unaltered for many years despite the availability of antimicrobial agents with proven in vitro activity, other non-antibiotic strategies should be investigated.

Users can search this database pertaining to respiratory conditions such as asthma, pneumonia, bronchitis, and tuberculosis. BackgroundThe National Occupational Respiratory Mortality System (NORMS) is developed and maintained by National Institute of Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC). This surveillance system includes respiratory conditions such as: asthma, pneumonia, bronchitis, tuberculosis, lung cancer, and silicosis, among others. User FunctionalityUsers can generate national- or occupation-specific queries. Users can gener ate tables, charts and maps containing the summary statistics such as number of deaths, crude death rates, age-adjusted death rates, and years of potential life lost (YPLL ). Users can also download the dataset and/or data queries into Microsoft Excel. Data NotesThis website provides data history regarding revisions to the dataset. Data from additional sources (i.e., population estimates, comparative standard population, and life-table values) are also available. National mortality data is derived from the National Center for Health Statistics (NCHS) multiple cause of death records. These data are updated annually since 1968, unless otherwise indicated. Data are available on national, state, and county levels. The most recent d ata available is from 2007.

Year- and age-dependent trend analysis—Proportion of pneumococcal pneumonia (PP) among community-acquired pneumonia (CAP).

Death rate of a population adjusted to a standard age distribution. As most causes of death vary significantly with people's age and sex, the use of standardised death rates improves comparability over time and between countries, as they aim at measuring death rates independently of different age structures of populations. The standardised death rates used here are calculated on the basis of a standard European population (defined by the World Health Organization). Detailed data for 65 causes of death are available in the database (under the heading 'Data').

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. Deaths involving COVID-19, influenza, and pneumonia reported to NCHS by jurisdiction of occurrence, place of death, and age group.

Pneumonia constitutes a substantial disease burden among adults overall and those who are elderly. We aimed to identify all studies investigating the disease burden among older adults (age, >=65 years) admitted to the hospital with pneumonia. We estimated the hospital admission rate and in-hospital case-fatality ratio (CFR) of pneumonia in older adults, stratified by age and economic status (industrialized vs developing), with data from a systematic review of studies published from 1996 through 2017 and from 8 unpublished population-based studies. We applied these rate estimates to population estimates for 2015 to calculate the global and regional burden in older adults who would have been admitted to the hospital with pneumonia that year. We estimated the number of in-hospital pneumonia deaths by combining in-hospital CFRs with hospital admission estimates from hospital-based studies. We identified 109 eligible studies; 73 used clinical pneumonia as the case definition, and 36 used radiologically confirmed pneumonia as the case definition. We estimated that, in 2015, 6.8 million episodes (uncertainty range [UR], 5.8-8.0 episodes) of clinical pneumonia resulted in hospital admissions of older adults worldwide. The hospital admission rate increased with advancing age and was higher in men. The total disease burden was likely underestimated when using the definition of radiologically confirmed pneumonia. Based on data from 52 hospital studies reporting data on pneumonia mortality, we estimated that about 1.1 million in-hospital deaths (UR, 0.9-1.4 in-hospital deaths) occurred among older adults. The burden of pneumonia requiring hospitalization among older adults is substantial. Appropriate prevention and management strategies should be developed to reduce its impact.

Death rate of a population adjusted to a standard age distribution. As most causes of death vary significantly with people's age and sex, the use of standardised death rates improves comparability over time and between countries, as they aim at measuring death rates independently of different age structures of populations. The standardised death rates used here are calculated on the basis of a standard European population (defined by the World Health Organization). Detailed data for 65 causes of death are available in the database (under the heading 'Data').

BackgroundSoluble programmed cell death 1 (sPD-1) and its ligand (sPD-L1) have emerged as potential biomarkers for early identification and risk stratification in patients with severe pneumonia (SP). However, there is a lack of robust laboratory evidence supporting their clinical utility. This study aimed to explore the relationship between sPD-1/sPD-L1 levels and clinical outcomes in SP patients.MethodsThis study included SP patients admitted to the Department of Critical Care Medicine at the Affiliated Hospital of Zunyi Medical University between November 2022 and December 2023. Patients were categorized into survivor and non-survivor groups based on 28-day clinical outcomes. Baseline characteristics and laboratory data were collected upon admission. Serum levels of sPD-1 and sPD-L1 were quantified using enzyme-linked immunosorbent assay. Cox regression analysis was performed to identify prognostic factors, and a nomogram was developed to predict outcomes. The predictive performance of sPD-1, sPD-L1, and their combined indices was evaluated using receiver operating characteristic (ROC) curve analysis.ResultsA total of 125 patients with severe pneumonia (SP) were included in this study. Compared to survivors, non-survivors were older, had more severe disease (as indicated by higher SOFA and APACHE II scores), and exhibited lower body mass index (BMI), hemoglobin levels, lymphocyte counts, CALLY index, and albumin levels. Additionally, non-survivors showed significantly elevated levels of systemic inflammatory markers (NLR, PLR, MLR, CLR, CAR, and SII) and higher serum sPD-1 concentrations. Multivariate Cox regression analysis identified age, SOFA score, and sPD-1 levels as independent risk factors for poor prognosis in SP patients. Restricted cubic spline (RCS) curves revealed a linear relationship between age, SOFA score, and the risk of poor prognosis. A nomogram incorporating age, SOFA score, and sPD-1 levels demonstrated strong predictive performance for 28-day mortality in SP patients, with an area under the curve (AUC) of 0.80. Incorporating sPD-1 measurements significantly improves the prognostic accuracy of both SOFA and APACHE II scores in critically ill patients.ConclusionsPD-1 levels were significantly elevated in non-surviving SP patients, suggesting its potential role as a biomarker for disease severity and immune dysregulation. The combination of sPD-1 with other clinical parameters may provide valuable insights into the prognosis and immune status of SP patients.